[{"orgOrder":0,"company":"Valo Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OPL-0401","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Not Applicable"},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Valo Health","amount2":2.7599999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Valo Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Valo Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OPL-0401","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Not Applicable"},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Valo Health","amount2":4.79,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4.79,"dosageForm":"","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Valo Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Valo Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK 1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Valo Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SCOPE Summit
                          Not Confirmed
                          SCOPE Summit
                          Not Confirmed

                          Details : The expanded collaboration will continue to utilize Valo's Opal Computational Platform, while Novo remains actively engaged in multiple small molecule preclinical drug discovery programs.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 08, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Novo Nordisk

                          Deal Size : $4,790.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          02

                          SCOPE Summit
                          Not Confirmed
                          SCOPE Summit
                          Not Confirmed

                          Details : OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1/2 inhibitor and a potential first-in-class oral option which is being evaluated for the treatment of diabetic retinopathy.

                          Product Name : OPL-0401

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 02, 2025

                          Lead Product(s) : OPL-0401

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          SCOPE Summit
                          Not Confirmed
                          SCOPE Summit
                          Not Confirmed

                          Details : OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1/2 inhibitor and a potential first-in-class oral option which is being evaluated for diabetic retinopathy.

                          Product Name : OPL-0401

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 04, 2024

                          Lead Product(s) : OPL-0401

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          SCOPE Summit
                          Not Confirmed
                          SCOPE Summit
                          Not Confirmed

                          Details : The collaboration will leverage Valo’s Opal Computational Platform including access to real-world patient data, AI-enabled small molecule discovery and Biowire® human tissue modelling platform to discover and develop novel treatments for cardiometabol...

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 25, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Novo Nordisk

                          Deal Size : $2,760.0 million

                          Deal Type : Collaboration

                          blank

                          05

                          SCOPE Summit
                          Not Confirmed
                          SCOPE Summit
                          Not Confirmed

                          Details : OPL-0401 is an inves­ti­ga­tion­al small mol­e­cule Rho kinase (ROCK) 1⁄2 inhibitor and a poten­tial first-in-class oral option for patients with NPDR, where the cur­rent treat­ment options are intrav­it­re­al injec­tions, surgery, or lase...

                          Product Name : OPL-0401

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 18, 2022

                          Lead Product(s) : OPL-0401

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank